Moderna said the Food and Drug Administration is delaying
its review of the company's vaccine for children ages 12 to 17 so it can
review reports that suggest the vaccine could cause heart problems in
some adolescents.
The FDA told Moderna on Friday that the review might not be completed
before Jan. 2022. As a result, Moderna said it would delay filing
a request for emergency use authorization of its vaccine for
children 6 to 11 years old.
|
No comments:
Post a Comment